Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Sarcoma 1Plasma cell 1

Conditions

Neoplasms, Plasma Cell 3Urinary Bladder Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Ovarian Neoplasms 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2zimberelimab 1vactosertib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1resiquimod 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine phosphate 1fludarabine 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1aldesleukin 1adavosertib 1X-Rays 1Uncertainty 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × poly ICLC × Plasma cell × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡